HBIO Harvard Bioscience, Inc.
Healthcare$5.68+1.61%ClosedMarket Cap: $25.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.49
P/S
0.29
EV/EBITDA
36.70
DCF Value
$0.96
FCF Yield
6.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.1%
Operating Margin
1.4%
Net Margin
-11.4%
ROE
-73.0%
ROA
-12.6%
ROIC
2.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $20.8M | 59.0% | $-119.0K | $-3.4M | $— | — |
| Q4 null | $23.7M | 59.7% | $1.9M | $-2.8M | $— | — |
| FY null | $86.5M | 53.0% | $-629.0K | $-56.7M | $— | — |
| Q3 null | $20.6M | 58.4% | $197.0K | $-1.2M | $— | — |
| Q2 null | $20.4M | 50.7% | $-819.0K | $-2.3M | $— | — |
| Q1 null | $21.8M | 56.0% | $-49.7M | $-50.3M | $— | — |
| Q4 null | $24.6M | 57.1% | $11.0K | $18.0K | $— | — |
| FY null | $94.1M | 58.2% | $-6.2M | $-12.4M | $— | — |
| Q3 null | $22.0M | 58.1% | $-1.9M | $-4.8M | $— | — |
| Q2 null | $23.1M | 57.2% | $-2.1M | $-2.9M | $— | — |
| Q1 null | $24.5M | 60.3% | $-2.3M | $-4.7M | $— | — |
| Q4 2023 | $28.2M | 53.1% | $282.0K | $-1.8M | $-0.43 | — |